Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study
Conclusions
Our results showed that real-world patients with advanced pancreatic cancer treated with FOLFIIRNOX or GnP had comparable survival with different safety profile.
Source: Pancreas - Category: Gastroenterology Tags: Original Articles Source Type: research
More News: Canada Health | Cancer | Cancer & Oncology | Eloxatin | Gastroenterology | Pancreas | Pancreatic Cancer | Study